- Time:
As the current biological product pipelines become more diverse, product demand and cost pressures are increasing. Process Intensification (PI) is one way that industry is exploring to overcome these challenges. PI can either be applied to an individual unit operation (Level 1) or a set of unit operations across upstream and downstream (Level 2 and above). These applications can enhance several measures, such as accelerated drug development, increased productivity, reduced footprint, flexibility, and improved drug quality.
Although many advances have been achieved when implementing PI in upstream, downstream often poses several challenges, with the foremost being low productivity, high footprint, and equipment downtime, all of which impact the cost of goods and annual facility output. Overcoming these fundamental challenges require reimagining the way batch downstream processes are carried out.
In this webinar, Abijar Bhori from Enzene Lifesciences and Sanket Jadhav from Sartorius will describe how bio-manufacturers can achieve up to 40% time savings per batch, 2-3 fold lower footprint and 16% additional annual capacity by transitioning from a batch to a connected downstream process through intensification, enabled by Sartobind® Q, CMM Hypercel and Resolute® BioSC system.
Join the webinar and learn:
- The current market trends, process, and business needs that drives the adoption of process intensification in the biopharmaceutical industry
- Different options for downstream process intensification
- Process development and scale-up of a connected DSP platform with Sartobind® Q, CMM Hypercel, and Resolute® BioSC
- Overall benefits of switching from batch to connected DSP
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Produced with support from:
Sanket Jadhav
External Collaborations Manager
Sartorius
